
US-based inSite Medical Technologies, Inc. manufactures and delivers safe epidural anesthesia devices.
Founded in Campbell, United States, InSite Medical Technologies, Inc. focuses on manufacturing medical devices with a core mission to enhance patient safety and care through innovative solutions. The company specializes in the safe delivery of epidural anesthesia and offers a unique Medical Technologies Analysis and Evaluation Program (MTAEP) to identify and assess emerging medical technologies. Their market focus is primarily within the United States, targeting healthcare providers and patients.
Notable affiliated individuals and investors remain undisclosed, but the company has achieved significant milestones in the medical device sector. Key achievements include the successful implementation of their MTAEP, which sets them apart in the industry by rigorously evaluating new technologies. Overall, InSite Medical Technologies has made a substantial impact on improving the safety and efficacy of epidural anesthesia delivery, contributing to better patient outcomes in the healthcare system.

Insightra Medical
insightra.com

Advanced Medical Device Technologies
advancedmdt.com

Medical Device Innovations

IntuiTap Medical

Intact Medical

Medical Engineering Innovations
mei-america.com

Anutra Medical
Medical Technologies Innovation Asia

ExploraMed NC7
exploramed.com

EpiEP
epiep.com

S.E.A. Medical Systems
seamedical.com

Channel Medsystems

Ionix Medical

Anesthesia Labs
anesthesialabs.com

Infused Medical Technology
Companies similar to InSite Medical Technologies include Insightra Medical, Advanced Medical Device Technologies, Medical Device Innovations and IntuiTap Medical.
InSite Medical Technologies was founded in 2009.
InSite Medical Technologies' headquarters is located in Saratoga, CA, US.
InSite Medical Technologies' most recent funding round was for $705.1k (USD) in June 2012.
As of Jun 5, 2012, InSite Medical Technologies has raised a total of $2.2M (USD).
InSite Medical Technologies has 5 employees as of Feb 5, 2024.